MarkMonitor Reports Continuing Rise In Online Abuse Of Top Drug Brands MarkMonitor®, the global leader in enterprise brand protection, released the Summer 2008 Brandjacking Index™, reporting that brandjackers increasingly abuse top-ranked pharmaceutical brands, endangering consumers via a supply chain compromised by the sale of questionable
prescription drugs through dubious online pharmacies and exchange sites.
Source: www.medicalnewstoday.comBT Business Helps Flexible Workers With Launch Of 'Get Fit For Mobile Working' BT Business has launched a practical guide - Get fit for mobile working - to help businesses tackle the problems encountered by some of the UK's 14 million mobile workers. The guide is designed to help mobile workers to avoid the back, neck and arm problems that can arise as a result of working in unfamiliar environments with a poor posture. Official figures show that back, neck and arm problems are the most common occupational illnesses in the UK. Over a fifth (20.
Source: www.medicalnewstoday.comAlgeta Reports Positive Headline Phase II Data On Pain Palliation With Alpharadin Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose. Pain palliation is an important quality of life benefit in metastatic cancer patients.
Source: www.medicalnewstoday.comDURECT Announces The IND Submission For A Third Abuse-Resistant Opioid Pain Medication Based On Its ORADUR(TM) Technology DURECT Corporation (Nasdaq: DRRX) reported that Pain Therapeutics (Nasdaq: PTIE), its licensee, has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for an abuse-resistant opioid pain drug candidate based on DURECT's patented ORADUR(TM) technology.
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 PM
